ArticleCancer immunology, immunotherapy : CII2019

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma.

Charlotte M Huijts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.